Source: NPR
The U.S. Army is set to grant an exclusive license for a pharmaceutical group to sell a new vaccine for Zika that was developed last year.
State leaders and health activists are expressing concerns over the potentially high price for the vaccine that will make it inaccessible, unaffordable to many states – especially those with low funding for health care.
Now, public officials and organizations have urged the U.S. army to stall the license until the pharmaceutical group, Sanofi Pasteur, “agrees to reasonable price terms.”
Because the vaccine is not yet available on the market, it is difficult to predict the price point for the new vaccine.
Read full story at: NPR